BioVie Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
BioVie Inc. (BIVI) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $8.98 million as of 2026-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Notes
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2026-08-13
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $8.98M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $13.10M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $20.54M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $24.98M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2026-06-30 | $8.98M 10-K · filed 2026-08-13 |
| 2026-03-31 | $13.10M S-1/A · filed 2026-08-06 |
| 2025-12-31 | $20.54M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $24.98M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $17.54M 10-K · filed 2026-08-13 |
| 2025-03-31 | $23.15M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $24.41M 10-Q · filed 2025-02-11 |
| 2024-09-30 | $20.02M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $23.84M S-1/A · filed 2026-08-06 |
| 2024-03-31 | $30.35M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $20.23M 10-Q · filed 2024-02-13 |
| 2023-09-30 | $21.21M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $33.94M 10-K · filed 2024-09-30 |
| 2023-03-31 | $43.80M 10-Q · filed 2023-05-12 |
| 2022-06-30 | $18.64M 10-K · filed 2023-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |